Detalhe da pesquisa
1.
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
Mol Ther
; 31(4): 1033-1045, 2023 04 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36793213
2.
Identification of CD105 (endoglin) as novel risk marker in CLL.
Ann Hematol
; 101(4): 773-780, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35044512
3.
Mass spectrometry for quality control of bispecific antibodies after SDS-PAGE in-gel digestion.
Biotechnol Bioeng
; 118(8): 3069-3075, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33988851
4.
Identification of CD318 (CDCP1) as novel prognostic marker in AML.
Ann Hematol
; 99(3): 477-486, 2020 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-31965270
5.
Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Int J Cancer
; 145(7): 1935-1945, 2019 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30860598
6.
A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells.
Mol Ther
; 24(2): 298-305, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26581163
7.
Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.
Mol Ther
; 24(9): 1634-43, 2016 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27380762
8.
Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
J Immunol
; 193(8): 4261-72, 2014 Oct 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25217158
9.
Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.
Mol Ther
; 23(4): 648-55, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25578618
10.
An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
Int J Cancer
; 136(5): 1073-84, 2015 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-25046567
11.
An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.
Front Immunol
; 15: 1343929, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38322253
12.
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3).
Front Oncol
; 14: 1351901, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38410109
13.
Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.
Sci Transl Med
; 16(737): eadh1988, 2024 Mar 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38446900
14.
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients.
Biomark Res
; 12(1): 50, 2024 May 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38735945
15.
Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro.
Front Immunol
; 14: 1112505, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36969164
16.
IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
Front Immunol
; 14: 1163136, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37122707
17.
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.
J Hematol Oncol
; 16(1): 96, 2023 08 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37587502
18.
Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies.
J Immunother Cancer
; 10(2)2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35110356
19.
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro.
J Cancer Res Clin Oncol
; 148(10): 2759-2771, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-35551463
20.
B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma.
Front Immunol
; 13: 1002898, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36275693